SCHEMBL595753

SCHEMBL595753

CNCCOc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 2/20 1.00
HTR1D P28221 1/20 1.00
DRD4 P21917 6/20 0.63
DRD2 P14416 5/20 0.63
DRD3 P35462 5/20 0.63
CHRNB2 P17787 1/20 0.61
CHRNA4 P43681 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.59
KCNA3 P22001 1/20 0.58
MTNR1A P48039 1/20 0.58
MTNR1B P49286 1/20 0.58
GAA P10253 1/20 0.55
KDM4E B2RXH2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10921722 0.98 HTR1B (0.96) HTR1BHTR1DDRD4DRD2DRD3
Iodide SCHEMBL30481083 0.98 HTR1B (0.96) HTR1BHTR1DDRD4DRD2DRD3
SCHEMBL1109801 0.93 HTR1B (1.00) HTR1BHTR1DDRD4DRD2DRD3
SCHEMBL23067924 0.88 HTR1B (0.78) HTR1BHTR1DDRD4DRD2DRD3
SCHEMBL23067891 0.88 HTR1B (0.78) HTR1BHTR1DDRD4DRD2DRD3
Acetamide SCHEMBL6136609 0.87 HTR1B (0.76) HTR1BHTR1DDRD4DRD2DRD3
Tetradecane SCHEMBL29054434 0.87 HTR1B (0.76) HTR1BHTR1DDRD4DRD2DRD3
SCHEMBL6849557 0.87 HTR1B (0.88) HTR1BHTR1DDRD4DRD2DRD3
SCHEMBL20251326 0.86 L3MBTL1 (0.81) HTR1BHTR1DL3MBTL1
SCHEMBL13886634 0.86 HTR1B (0.85) HTR1BHTR1DDRD4DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115745457-A High-adaptability concrete superplasticizer, preparation method and application thereof 南京博特新材料有限公司 2023-03-07 CN claimed
CN-115725035-A Slump-retaining concrete superplasticizer, preparation method and application thereof 博特新材料泰州有限公司 2023-03-03 CN claimed
EP-2661436-B1 NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2016-04-13 EP claimed
US-9000107-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2015-04-07 US claimed
US-6768024-B1 CONTROLLING OBESITY, SEXUAL DYSFUNCTION OR INFLAMMATION LION BIOSCIENCE AG (DE) 2004-07-27 US claimed
EP-1060178-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER (US) 2003-09-03 EP claimed
WO-2002012166-A2 TRIAMINE DERIVATIVE MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME LION BIOSCIENCE AG (DE) 2002-02-14 WO claimed
EP-0998934-A1 REMEDIES FOR INTRAMEDULLARY DISEASES TORAY INDUSTRIES, INC. (JP) 2000-05-10 EP claimed
EP-0226475-A1 Diphenoxyethyl amine derivatives, process for their preparation and pharmaceutical compositions containing them Albert ROLLAND S.A. Société dite (FR) 1987-06-24 EP claimed
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20250345785-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS BIO RAD LABORATORIES INC (US) 2025-11-13 US disclosed
US-12364978-B2 Anionic exchange-hydrophobic mixed mode chromatography resins BIO-RAD LABORATORIES, INC. (US) 2025-07-22 US disclosed
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-04-03 US disclosed
US-12202817-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2025-01-21 US disclosed
EP-0147510-A1 Dibenzopyran derivatives FISONS CORPORATION (US) 1985-07-10 EP disclosed
US-4500529-A ANTIARRHYTHMIA AGENT A. H. ROBINS COMPANY, INCORPORATED (US) 1985-02-19 US disclosed
EP-0114374-A1 Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines BAYER AG (DE) 1984-08-01 EP disclosed
EP-0066987-A2 N-(aryloxyalkyl)-N'-(amino-alkyl) ureas A.H. ROBINS COMPANY, INCORPORATED (US) 1982-12-15 EP disclosed
EP-0064487-A1 New substituted 3-(parasubstituted)phenoxy-1-alkylamino-propanol-2-s, as well as process for their preparation, pharmaceutical preparations containing same, and method for treating cardiac failure Aktiebolaget Hässle (SE) 1982-11-10 EP disclosed
US-4304778-A 4-Aminoquinazoline derivatives having fungicidal, anti-insect and acaricidal properties SANKYO COMPANY LIMITED (JP) 1981-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250345785-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS ABCG2, SLC7A1, MSR1 HTR1B 1932/4885HTR1D 2519/4885DRD4 1739/4885
US-12364978-B2 Anionic exchange-hydrophobic mixed mode chromatography resins ABCG2, SLC7A1, MSR1 HTR1B 1932/4885HTR1D 2519/4885DRD4 1739/4885
US-12202817-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI HTR1B 2346/4885HTR1D 2838/4885DRD4 3932/4885
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI HTR1B 2346/4885HTR1D 2838/4885DRD4 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.